Danicopan PMS in Korea

Recruiting now

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria

In brief

As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.

Key facts

Study ID

NCT07457151

Run by

AstraZeneca

People needed

8

Starts

2026-04-10

Expected to finish

2028-06-27

Last updated by the study team

2026-07-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients eligible for and treated with Danicpan as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patient with PNH in Korea
• Provision of a signed and dated written informed consent by the patient or their legally acceptable representative

You may not qualify if…

• Participation in any concurrent interventional trials during the period of study drug treatment
• Other off-label indications according to the approved label in Korea

Where it is running

• Research Site — Busan, South Korea (enrolling)
• Research Site — Hwasun-gun, South Korea (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.